Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea

Core Insights - Nxera Pharma has announced positive top-line results from a Phase 3 study of daridorexant 50 mg for treating insomnia in South Korea, with plans to submit a marketing authorization application in Q1 2026 and expected approval in Q1 2027 [1][7] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet needs, operating in Japan and globally, and listed on the Tokyo Stock Exchange [12] - The company has established a commercial presence in Japan and is advancing an extensive pipeline through its unique drug discovery platform [12] Product Information - Daridorexant is a dual orexin receptor antagonist approved in Japan as QUVIVIQ® and is marketed in various regions including the US, Canada, and Europe [2][7] - The Phase 3 trial demonstrated significant improvements in subjective total sleep time, sleep onset latency, and wake after sleep onset compared to placebo, with p-values less than 0.0001 [5][7] Market Context - Insomnia affects approximately 15-25% of the adult population in South Korea, translating to about 6.5-11 million individuals, with a notable increase in chronic insomnia patients from 597,529 in 2018 to 722,440 in 2022 [3][10] - The condition is particularly prevalent among women and older adults, with 50% of treated patients aged 60 or above [10] Clinical Study Details - The Phase 3 trial was a multicenter, randomized, double-blind, placebo-controlled study involving adult and elderly patients, with participants receiving either daridorexant 50 mg or placebo for 28 days [4][5] - The incidence of treatment-emergent adverse events was similar between the daridorexant and placebo groups, reported at 13.41% and 14.81% respectively [5]